Aclidinium/formoterol
Aclidinium/formoterol (trade names Duaklir and Brimica) is a combination drug for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[1]
| Combination of | |
|---|---|
| Aclidinium bromide | Long-acting muscarinic antagonist |
| Formoterol | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Brimica Genuair, Duaklir Genuair |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
References
- "Duaklir Genuair". European Medicines Agency. 2014-12-05. Retrieved 2015-06-01.
| Adrenergics, inhalants |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids | |||||||||
| Anticholinergics/ muscarinic antagonist | |||||||||
| Mast cell stabilizers | |||||||||
| Xanthines | |||||||||
| Eicosanoid inhibition |
| ||||||||
| Others/unknown | |||||||||
| Combination products | |||||||||
| |||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.